Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
STEP-1 (Semaglutide 2.4 mg for Obesity, NEJM 2021): At the Wegovy dose of 2.4 mg, participants lost an average of 14.9% of their body weight over 68 weeks
References to specific products, dosing schedules, or clinical protocols in this article are for informational and educational purposes only and do not constitute an endorsement of any specific treatment approach
Switching medications If semaglutide side effects remain unmanageable despite dose adjustments, switching to an alternative GLP-1 receptor agonist or to tirzepatide may be appropriate
Reduced calorie intake creates a calorie deficit, which not only metabolizes stored fats to promote fat loss but also muscle tissues to meet the protein needs of the body
US$ 21.88
US$ 25.71
US$ 29.12
US$ 27.65
